Several other equities analysts also recently weighed in on NEOS. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the stock a buy rating in a research report on Wednesday. Zacks Investment Research raised Neos Therapeutics from a hold rating to a buy rating and set a $9.00 price target for the company in a research report on Wednesday. ValuEngine raised Neos Therapeutics from a strong sell rating to a sell rating in a research report on Saturday, August 12th. Royal Bank Of Canada set a $12.00 price target on Neos Therapeutics and gave the stock an outperform rating in a research report on Tuesday, August 8th. Finally, BMO Capital Markets reissued an outperform rating and set a $15.00 price target on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Neos Therapeutics presently has an average rating of Hold and an average price target of $14.00.
Shares of Neos Therapeutics (NASDAQ:NEOS) traded up 0.331% during mid-day trading on Wednesday, hitting $7.575. The company had a trading volume of 659,999 shares. The firm has a 50-day moving average price of $8.77 and a 200 day moving average price of $8.77. The firm’s market capitalization is $212.71 million. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $9.60.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The firm had revenue of $4.91 million during the quarter. On average, equities research analysts forecast that Neos Therapeutics will post ($3.11) earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd purchased a new position in Neos Therapeutics during the second quarter worth $118,000. State Street Corp grew its position in shares of Neos Therapeutics by 29.6% in the second quarter. State Street Corp now owns 316,855 shares of the company’s stock valued at $2,312,000 after purchasing an additional 72,395 shares during the period. DAFNA Capital Management LLC grew its position in shares of Neos Therapeutics by 120.3% in the second quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock valued at $1,532,000 after purchasing an additional 114,600 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Neos Therapeutics in the second quarter valued at $146,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Neos Therapeutics in the second quarter valued at $204,000. 44.29% of the stock is owned by institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.